Track Lifecore Biomedical Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Lifecore Biomedical Inc. Common Stock LFCR · Stock Open Lifecore Biomedical Inc. Common Stock in new tab

6.42 USD
EPS
-1.27
P/B
-3.32
Beta
0.97
Loading chart...
Key Metrics
Earnings dateMarch 15, 2027
EPS-1.27
Book Value-1.94
Price to Book-3.32
Debt/Equity971.70
% Insiders3.185%
Growth
Revenue Growth-0.19%
Estimates
Forward P/E-8.92
Forward EPS-0.72

DCF valuation

Model fair value for Lifecore Biomedical Inc. Common Stock (LFCR)
Result
Sign in to run the valuation for LFCR.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Lifecore Biomedical Inc. Common Stock Logo Lifecore Biomedical Inc. Common Stock Analysis (LFCR)

United States Health Care Official Website Stock

Is Lifecore Biomedical Inc. Common Stock a good investment? Lifecore Biomedical Inc. Common Stock (LFCR) is currently trading at 6.42 USD.

Earnings Schedule: Lifecore Biomedical Inc. Common Stock is expected to release its next earnings report on March 15, 2027. The market consensus estimate for Forward EPS is -0.72.

Investor FAQ

Does Lifecore Biomedical Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Lifecore Biomedical Inc. Common Stock?

Lifecore Biomedical Inc. Common Stock is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 15, 2027. The company currently has a trailing EPS of -1.27.

Company Profile

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Exchange Ticker
NMS (United States) LFCR
NMS (United States) LNDC
FRA (Germany) LDE.F
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion